Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
Adjuvante therapie voor melanoom: historische, recente en toekomstige ontwikkelingen
aug 2019 | Dermato-oncologie